METAP2 and cancer: To establish AUTOTAC as a versatile degradation platform, Ji et al. developed AUTOTACs to target soluble protein such as estrogen receptor beta (ERβ), androgen receptor (AR), and methionine aminopeptidase 2 (MetAP2) [17]; these cancer targets were previously explored in PROTAC research [46].